

Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














Sofinnova Ventures













Home
Team
Portfolio
About
News
Contact
HealthQuest Capital
Sofinnova Partners
Investor Portal




Partners for Development Equity in Biotech





Sofinnova Ventures News

September 14, 2017 Heather Behanna to speak at World Anti-Microbial Resistance Congress 2017
May 30, 2017 Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership
April 11, 2017 Jim Healy to Speak at Cancer Advance Boston
February 06, 2017 Charlotte Shropshire to Speak at SuperReturn US West
October 24, 2016 Sofinnova Steps Up
October 17, 2016 Sofinnova Raises $650 Million for Oversubscribed Fund X
June 09, 2016 Jim Healy to Speak at BIO on Market & Political Pressures



Portfolio News

June 15, 2017 Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals
March 28, 2017 Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy
March 22, 2017 BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital
January 25, 2017 ObsEva SA Announces Pricing of Initial Public Offering
January 17, 2017 ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
December 19, 2016 Novartis bolsters innovative dermatology portfolio through
acquisition of Ziarco Group Limited
November 28, 2016 Galera Therapeutics Receives $15M from Sofinnova Ventures
November 28, 2016 Galera Therapeutics Expands Series B to $57 Million



Contact
Menlo Park
3000 Sand Hill Road, Building 4, Suite 250
Menlo Park, CA 94025
Telephone (650) 681-8428
San Diego
1250 Prospect Street, Ocean Level - 4
La Jolla, CA 92037
Telephone (858) 551-4880
For inquiries please email: info@sofinnova.com
For information about our sister firm Sofinnova Partners based in Paris, France, please visit www.sofinnova.fr. 

ÂŠÂ 2016 Sofinnova Ventures, Inc.











Sofinnova Management VI, L.L.C. - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Sofinnova Management VI, L.L.C.
Check out list of companies and businesses related to Sofinnova Management VI, L.L.C.. Find out Sofinnova Management VI, L.L.C. address and contact details. View other people related to Sofinnova Management VI, L.L.C. - coworkers, colleagues, companions, etc.
Address:   

140 GEARY STREET, 10TH FLOOR  SAN FRANCISCO 94108 CA




Companies related to Sofinnova Management VI, L.L.C.
CIKCompany NamePositionCompany Address0001316175Anthera Pharmaceuticals Inc10% Owner 25801 INDUSTRIAL BOULEVARD, SUITE B  HAYWARD 94545




Sofinnova Management VI, L.L.C. on the Web
Persons related to Sofinnova Management VI, L.L.C. - Anthera Pharmaceuticals IncNamePositionCityAlain  AzanMENLO PARKAlain  AzanMENLO PARKAnnette  BianchiDirector SAN BRUNOAnnette  BianchiSAN BRUNOEric  BuatoisMENLO PARKKlara  DickinsonChief Regulatory Officer SOUTH SAN FRANCISCOBOGDAN  DZIURZYNSKI HAYWARDBOGDAN  DZIURZYNSKIHAYWARDBOGDAN  DZIURZYNSKIDirector HAYWARDBOGDAN  DZIURZYNSKIDirector HAYWARDBOGDAN  DZIURZYNSKI HAYWARDSTEVEN B  ENGLE SAN DIEGOSTEVEN B  ENGLEBERKELEYSTEVEN B  ENGLE HAYWARDUrsula  FritschVP, Glob. Reg. & Compliance HAYWARDBrent  FursePARSIPPANYJAMES  HEALYDirector MENLO PARKJAMES  HEALY HAYWARDJAMES  HEALYDirector HAYWARDCHRISTOPHER S  HENNEY SEATTLECHRISTOPHER S  HENNEY HAYWARDCHRISTOPHER S  HENNEY HAYWARDCHRISTOPHER S  HENNEYDirector HAYWARDColin  HislopChief Medical Officer HAYWARDColin  HislopChief Medical Officer HAYWARDColin  HislopChief Medical Officer HAYWARDSAMUEL D  ISALYNEW YORKSAMUEL D  ISALYNEW YORKSAMUEL D  ISALYNEW YORKSAMUEL D  ISALYNEW YORKGEORGINA  KILFOILSVP, Prod. Dev. & Project Mngm HAYWARDGEORGINA  KILFOILSVP,Product Dev.& Project Mgmt HAYWARDGEORGINA  KILFOILSVP,Product Dev.& Project Mgmt HAYWARDStephen  LauVP, Corp. & Business Dev. HAYWARDA. Rachel  LehenyDirector HAYWARDMAY  LIUPrincipal Accounting Officer HAYWARDCHRISTOPHER P.  LOWEChief Financial Officer & CBO HAYWARDCHRISTOPHER P.  LOWEC.F.O. and C.B.O. HAYWARDCHRISTOPHER P.  LOWEC.F.O. and C.B.O. HAYWARDCHRISTOPHER P.  LOWECFO and Chief Business Officer HAYWARDBrian  Mueller NOVATOBrian  MuellerHAYWARDBrian  Mueller HAYWARDBrian  Mueller HAYWARDDEBRA  ODINKChief Technology Officer HAYWARDDEBRA  ODINKChief Technology Officer HAYWARDDEBRA  ODINKChief Technology Officer HAYWARDCharles V  OlsonChief Technology Officer HAYWARDORBIMED ADVISORS LLCDirector NEW YORKORBIMED ADVISORS LLCDirector NEW YORKORBIMED ADVISORS LLC10% Owner NEW YORKORBIMED ADVISORS LLCDirector NEW YORKOrbiMed Capital GP IV LLCNEW YORKOrbiMed Capital GP IV LLCNEW YORKOrbiMed Capital GP IV LLCNEW YORKJames  PenningtonHAYWARDJAMES E  PENNINGTONHAYWARDMICHAEL  POWELLMENLO PARKPhilip  Sager HAYWARDPhilip  Sager HAYWARDPhilip  Sager HAYWARDALAN E  SALZMANSAN BRUNOALAN E  SALZMANSAN BRUNODonald J  SantelDirector HAYWARDWILLIAM R  SHANAHAN JRChief Medical Officer SAN DIEGOSofinnova Venture Affiliates VI LPMENLO PARKSofinnova Venture Partners VI GmbH & Co. KGMENLO PARKSOFINNOVA VENTURE PARTNERS VI L P10% Owner SAN FRANCISCOSOFINNOVA VENTURE PARTNERS VI L P10% Owner MENLO PARKDANIEL K  SPIEGELMAN HAYWARDDANIEL K  SPIEGELMAN HAYWARDDANIEL K  SPIEGELMANDirector HAYWARDDavid E.  ThompsonDirector HAYWARDDavid E.  Thompson HAYWARDDavid E.  Thompson HAYWARDJOHN CRAIG  THOMPSONPresident & CEO SAN DIEGOPeter A.  ThompsonDirector HAYWARDJoaquim  TriasSr. VP, Preclinical Developmen HAYWARDPAUL F  TRUEXExecutive Chaiman HAYWARDPAUL F  TRUEXPresident and CEO HAYWARDPAUL F  TRUEXPresident and CEO HAYWARDPAUL F  TRUEXPresident and CEO HAYWARDPAUL F  TRUEXPresident and CEO HAYWARDVANTAGEPOINT VENTURE ASSOCIATES IV LLC10% Owner SAN BRUNOVANTAGEPOINT VENTURE ASSOCIATES IV LLC10% Owner SAN BRUNOVANTAGEPOINT VENTURE PARTNERS IV LPSAN BRUNOVANTAGEPOINT VENTURE PARTNERS IV LPSAN BRUNOVANTAGEPOINT VENTURE PARTNERS IV PRINCIPALS  FUND LPSAN BRUNOVANTAGEPOINT VENTURE PARTNERS IV PRINCIPALS FUND LPSAN BRUNOVANTAGEPOINT VENTURE PARTNERS IV Q LPSAN BRUNOVANTAGEPOINT VENTURE PARTNERS IV Q LPSAN BRUNOZenyaku Kogyo Co., Ltd.TOKYOSANFORD S  ZWEIFACH HAYWARDSANFORD S  ZWEIFACH HAYWARDSANFORD S  ZWEIFACH HAYWARD
Potentially same personNameCityCountrySofinnova Management VI, L.L.C.SAN FRANCISCOCASofinnova Management VI, L.L.C.MENLO PARKCASofinnova Management VI, L.L.C.MENLO PARKCA












 









Insider Trading - Mehra Anand - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Mehra Anand





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-12-15Sale
2016-12-199:03 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
349,656
$53.46
$18,691,892
1,184,714(Indirect)
View


2016-12-09Sale
2016-12-137:25 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
122,532
$55.17
$6,759,555
1,368,274(Indirect)
View


2016-10-20Sale
2016-10-244:49 pm
Marinus Pharmaceuticals Inc
MRNS
Mehra AnandSofinnova Venture Partners Vi L PSofinnova Venture Partners Vi Gmbh & Co. KgSofinnova Venture Affiliates Vi LpSofinnova Management Vi L.L.C.Buatois EricHealy JamesAzan AlainPowell Michael10% Owner
750,683
$1.389
$1,042,699
1,134,851(Indirect)
View


2016-08-10Sale
2016-08-124:30 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
29,963
$60.13
$1,801,817
1,400,237(Indirect)
View


2016-08-08Sale
2016-08-107:13 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
100
$60.47
$6,047
1,407,137(Indirect)
View


2016-08-03Sale
2016-08-057:30 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
5,064
$60
$303,840
1,407,689(Indirect)
View


2016-08-01Sale
2016-08-036:27 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
22,665
$60.03
$1,360,580
1,412,301(Indirect)
View


2016-05-31Sale
2016-06-023:24 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
500
$60
$30,000
1,434,966(Indirect)
View


2015-11-25Sale
2015-11-307:38 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
22,961
$60.01
$1,377,943
1,440,816(Indirect)
View


2015-11-09Sale
2015-11-128:25 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
130,605
$60.11
$7,850,870
1,563,077(Indirect)
View


2015-10-13Purchase
2015-10-131:26 pm
Aclaris Therapeutics Inc.
ACRS
Mehra AnandDirector10% Owner
409,090
$11
$4,499,990
2,289,480(Indirect)
View


2015-10-07Sale
2015-10-097:59 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
529,544
$45.46
$24,074,435
2,033,074(Indirect)
View


2015-10-05Purchase
2015-10-064:09 pm
Mirna Therapeutics Inc.
MIRN
Sofinnova Venture Partners Viii L.P.Sofinnova Management Viii L.L.C.Healy JamesAkkaraju SrinivasMehra Anand10% Owner
857,142
$7
$5,999,994
2,974,811(Direct)
View


2015-05-12Purchase
2015-05-149:19 pm
Atyr Pharma Inc
LIFE
Sofinnova Venture Partners Ix L.P.Sofinnova Management Ix L.L.C.Healy JamesPowell MichaelMehra Anand10% Owner
320,000
$14
$4,480,000
1,866,126(Direct)
View


2015-04-14Sale
2015-04-167:23 pm
Aerie Pharmaceuticals Inc
AERI
Mehra AnandDirector
425,000
$33.64
$14,297,765
916,657(Indirect)
View


2015-02-04Purchase
2015-02-068:06 pm
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
225,000
$23
$5,175,000
2,118,576(Indirect)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-08-03Option Award
2016-08-057:32 pm
N/A2026-08-03
Marinus Pharmaceuticals Inc
MRNS
Mehra AnandDirector
7,700
$1.5
7,700(Direct)
View


2016-08-03Option Award
2016-08-057:32 pm
N/A2026-08-03
Marinus Pharmaceuticals Inc
MRNS
Mehra AnandDirector
3,300
$0
7,700(Direct)
View


2016-06-29Option Award
2016-07-014:16 pm
N/A2026-06-28
Aclaris Therapeutics Inc.
ACRS
Mehra AnandDirector10% Owner
6,632
$18.32
6,632(Direct)
View


2016-06-01Option Award
2016-06-034:32 pm
N/A2026-05-31
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
6,000
$56.22
6,000(Direct)
View


2015-10-13Conversion
2015-10-131:26 pm
N/AN/A
Aclaris Therapeutics Inc.
ACRS
Mehra AnandDirector10% Owner
1,880,390
$0
2,289,480(Indirect)
View


2015-10-13Conversion
2015-10-131:26 pm
N/AN/A
Aclaris Therapeutics Inc.
ACRS
Mehra AnandDirector10% Owner
2,000,000
$0
2,289,480(Indirect)
View


2015-10-13Conversion
2015-10-131:26 pm
N/AN/A
Aclaris Therapeutics Inc.
ACRS
Mehra AnandDirector10% Owner
2,424,242
$0
2,289,480(Indirect)
View


2015-10-13Conversion
2015-10-131:26 pm
N/AN/A
Aclaris Therapeutics Inc.
ACRS
Mehra AnandDirector10% Owner
2,063,107
$0
2,289,480(Indirect)
View


2015-10-05Conversion
2015-10-064:09 pm
N/AN/A
Mirna Therapeutics Inc.
MIRN
Sofinnova Venture Partners Viii L.P.Sofinnova Management Viii L.L.C.Healy JamesAkkaraju SrinivasMehra Anand10% Owner
1,244,269
$0
2,974,811(Direct)
View


2015-10-05Conversion
2015-10-064:09 pm
N/AN/A
Mirna Therapeutics Inc.
MIRN
Sofinnova Venture Partners Viii L.P.Sofinnova Management Viii L.L.C.Healy JamesAkkaraju SrinivasMehra Anand10% Owner
583,559
$0
2,974,811(Direct)
View


2015-10-05Other
2015-10-064:09 pm
N/AN/A
Mirna Therapeutics Inc.
MIRN
Sofinnova Venture Partners Viii L.P.Sofinnova Management Viii L.L.C.Healy JamesAkkaraju SrinivasMehra Anand10% Owner
289,841
$0
2,974,811(Direct)
View


2015-10-05Conversion
2015-10-064:09 pm
N/AN/A
Mirna Therapeutics Inc.
MIRN
Sofinnova Venture Partners Viii L.P.Sofinnova Management Viii L.L.C.Healy JamesAkkaraju SrinivasMehra Anand10% Owner
1,244,269
$0
2,974,811(Direct)
View


2015-10-05Conversion
2015-10-064:09 pm
N/AN/A
Mirna Therapeutics Inc.
MIRN
Sofinnova Venture Partners Viii L.P.Sofinnova Management Viii L.L.C.Healy JamesAkkaraju SrinivasMehra Anand10% Owner
583,559
$0
2,974,811(Direct)
View


2015-07-20Option Award
2015-07-228:57 pm
N/A2025-07-20
Marinus Pharmaceuticals Inc
MRNS
Mehra AnandDirector10% Owner
6,300
$14.3
6,300(Direct)
View


2015-05-12Conversion
2015-05-149:19 pm
N/AN/A
Atyr Pharma Inc
LIFE
Sofinnova Venture Partners Ix L.P.Sofinnova Management Ix L.L.C.Healy JamesPowell MichaelMehra Anand10% Owner
1,546,126
$0
1,866,126(Direct)
View


2015-05-12Conversion
2015-05-149:19 pm
N/AN/A
Atyr Pharma Inc
LIFE
Sofinnova Venture Partners Ix L.P.Sofinnova Management Ix L.L.C.Healy JamesPowell MichaelMehra Anand10% Owner
14,968,722
$0
1,866,126(Direct)
View


2015-04-14Exercise
2015-04-167:23 pm
N/AN/A
Aerie Pharmaceuticals Inc
AERI
Mehra AnandDirector
150,000
$5
916,657(Indirect)
View


2015-04-14Other
2015-04-167:23 pm
N/AN/A
Aerie Pharmaceuticals Inc
AERI
Mehra AnandDirector
22,066
$5
916,657(Indirect)
View


2015-04-14Exercise
2015-04-167:23 pm
N/AN/A
Aerie Pharmaceuticals Inc
AERI
Mehra AnandDirector
150,000
$5
916,657(Indirect)
View


2015-04-10Option Award
2015-04-146:51 pm
N/AN/A
Aerie Pharmaceuticals Inc
AERI
Mehra AnandDirector
1,700
$0
766,657(Direct)
View


2015-04-10Option Award
2015-04-146:51 pm
N/A2025-04-10
Aerie Pharmaceuticals Inc
AERI
Mehra AnandDirector
10,000
$32.3
766,657(Direct)
View


2015-02-04Conversion
2015-02-068:06 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
1,893,576
$0
2,118,576(Indirect)
View


2015-02-04Option Award
2015-02-068:06 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
30,222
$0
2,118,576(Indirect)
View


2015-02-04Conversion
2015-02-068:06 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Mehra AnandDirector
1,893,576
$0
2,118,576(Indirect)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 15:35:09 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  










Active Investments Portfolio | Sofinnova Ventures












Home
Team
Portfolio
About
News
Contact
HealthQuest Capital
Sofinnova Partners
Investor Portal





Active Investments
Selected Realized Investments
Remaining IT Investments



Active Investments



 
 


					Aclaris Therapeutics				 
				Specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. (NASDAQ: ACRS)






 
 


					Aerie Pharmaceuticals				 
				Clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. (NASDAQ: AERI)






 
 


					Alimera Sciences				 
				Specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. (NASDAQ: ALIM)






 
 


					Amarin				 
				Focused on improving the treatment of cardiovascular disease. The company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. (NASDAQ: AMRN)






 
 


					Anthera Pharmaceuticals				 
				Focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. (NASDAQ: ANTH)






 
 


					Antiva 				 
				Develop creatively designed therapeutics that dramatically improve health outcomes for patients suffering from diseases caused by HPV and other viruses.






 
 


					Ascendis Pharma				 
				Ascendis Pharma develops differentiated prodrug versions of high-value protein drugs, such as growth hormone.  (NASDAQ: ASND)






 
 


					aTyr Pharma				 
				Focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. (NASDAQ: LIFE)






 
 


					Audentes Therapeutics				 
				Committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology. (NASDAQ: BOLD)






 
 


					Auris Medical				 
				Prevention or treatment of inner ear disorders,  for acute inner ear tinnitus and for acute inner ear hearing loss.  (NASDAQ: EARS)






 
 


					BioClin Therapeutics				 
				Our strategy is to develop biologics for medical conditions where there has been no approved or satisfactory therapy. Our lead product, B-701, is a human antibody targeting FGFR3 (fibroblast growth factor receptor 3) being developed as a treatment for metastatic bladder cancer and achondroplasia (dwarfism).






 
 


					Catalyst Biosciences				 
				Creating novel catalytic biopharmaceutical products based on engineered human proteases.  






 
 


					Checkmate Pharmacueticals				 
				Developing novel approach to specifically activating the immune system to recognize and ultimately destroy tumor cells.






 
 


					Chiasma				 
				Late-stage biotech developing an oral drug candidate for acromegaly. (NASDAQ: CHMA)






 
 


					Coherus Biosciences				 
				A leading developer of high-quality therapeutics with a robust pipeline of biosimilar products. (NASDAQ: CHRS)








 
 


					Dauntless Pharmaceuticals				 
				Biopharmaceutical company focused on the development of specialty drugs.






 
 


					Edge Therapuetics				 
				Develops commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. (NASDAQ: EDGE)






 
 


					First Aid Shot Therapy				 
				Focused on the development and commercialization of a comprehensive portfolio of OTC pharmaceutical products in liquid 'shot' format. 






 
 


					Galera Therapeutics				 
				Galera Therapeutics is a private clinical-stage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways.






 
 


					Histogenics				 
				Combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. (NASDAQ: HSGX)






 
 


					Hyperion Therapeutics				 
				Focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. (NADSAQ: HPTX)






 
 


					Innocoll				 
				Developing and manufacturing a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies.   (NASDAQ: INNL)






 
 


					Merus				 
				Clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics to treat and potentially cure cancer patients.






 
 


					Mirna Therapeutics				 
				Developing tumor suppressor microRNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways. (NASDAQ: MIRN)






 
 


					Natera				 
				Develops and commercializes non-invasive methods for analyzing DNA. 






 
 


					NuCana 				 
				Developing and commercialising novel anti-cancer medicines including next generation nucleotide prodrugs.






 
 


					ObsEva				 
				Dedicated to the development of innovative drugs for women’s reproductive medicine including preterm labor. 







 
 


					Ocera				 
				Focused on the development of drugs to treat a broad range of gastrointestinal and liver diseases. (NASDAQ: OCRX)






 
 


					Ophthotech Corporation				 
				Specializing in the development of novel therapeutics to treat diseases of the eye.  (NASDAQ: OPHT)






 
 


					Principia Biopharma 				 
				Focused on discovering and developing first-in-class small molecule drugs within the fields of autoimmune disease and oncology that are potent and safe.







 
 


					Prothena 				 
				Advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion, including amyloidosis. (NASDAQ: PRTA)






 
 


					Spark Therapeutics				 
				Focused on developing curative, one-time gene therapy products including lead gene therapy candidate, for RPE65-related blindness. (NASDAQ: ONCE)







 
 


					Versartis				 
				Developing therapeutics for the treatment of endocrine disorders, including human growth hormones. (NASDAQ: VSAR) 






 
 


					Ziarco				 
				Ziarco is a private, clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular atopic dermatitis and psoriasis. These diseases impact the well-being of millions of children and adults globally by severely reducing quality of life.






 
 


					ZS Pharma				 
				Focused on the treatment of kidney and liver diseases including hyperkalemia. (NASDAQ: ZSPH)






© 2016 Sofinnova Ventures, Inc.




Active Investments Portfolio News

June 15, 2017Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals
March 28, 2017Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy
March 22, 2017BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital
January 25, 2017ObsEva SA Announces Pricing of Initial Public Offering
January 17, 2017ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
December 19, 2016Novartis bolsters innovative dermatology portfolio through
acquisition of Ziarco Group Limited
November 28, 2016Galera Therapeutics Receives $15M from Sofinnova Ventures
November 28, 2016Galera Therapeutics Expands Series B to $57 Million
July 21, 2016Dauntless Takes Flight with New Business Model for Starting Biotechs




















Sofinnova Management Vi, L.L.C. - Anthera Pharmaceuticals Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsSofinnova Management Vi, L.L.C.Anthera Pharmaceuticals (ANTH)Ten Percent Owner Not RankedSofinnova Management Vi, L.L.C.'s PerformanceSofinnova Management Vi, L.L.C. has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Insider Holdings 100.0% Anthera Pharmaceuticals (ANTH)$3MSee the Top Stocks by Insiders > Insider RolesAnthera Pharmaceuticals (ANTH): Ten Percent OwnerSee the Top 25 Corporate Insiders > Most Profitable Insider TradeStock: Anthera Pharmaceuticals (ANTH)Transaction Type: Informative BuyDates: Mar 08, 2010 - Mar 08, 2011Gain: -7.8%See the Latest Stocks Traded by Insiders > Sofinnova Management Vi, L.L.C.'s Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateANTHAnthera PharmaceuticalsTen Percent Owner$2,830,405Uninformative Buy$8,462,756.68Mar 08, 2010Success Rate on Stock0 out of 1 profitable transactions on ANTHAverage Profit on StockAverage return per transaction on ANTH -7.8% Track Record Showing:All TransactionsInformative TransactionsDateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Mar 08, 2010 Informative Buy $3M 2,182,771 $56.32 -7.80%  Mar 08, 2010 Uninformative Buy $8M 1,253,635 $56.32 N/A See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by


































BrightScope | Advisor Pages - Find a Financial Advisor or Advisory Firm 































































[[getSearchTypeDisplayName(searchType)]]


Advisor

Funds

Firms

401k Plans









































































General Search










Advisors
Advisory Firms
Financial Q&A
401k Plans
Funds


Search










Home  >  BrightScope Advisor Pages  >  Find a Financial Advisory Firm
    




Advisor Search
Firm Search
Advisors by City


    
        Find a Financial Advisory Firm
    





Search




Firm Name







Active firms only





City



State


Alabama
Alaska
American Samoa
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Guam
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Northern Marinara Islands
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming



Firm Service Areas



Financial Planning



Estate Planning



Comprehensive Financial Planning



Retirement Planning



College Planning



Charitable Planning



Other Financial Planning



Tax Planning





Insurance



Life Insurance



Health Insurance



Long-Term Care Insurance



Annuities



Property & Casualty Insurance



Business Insurance



Other Insurance





Pension Consulting



401k



403b



457



Defined Benefit



Other Pension Consulting





Portfolio Management



Individuals and/or Small Businesses



Investment Companies



Businesses or Institutional Clients



Other Portfolio Management





Accounting & Tax



Tax Advice



Other Tax





Legal



Legal Planning



Legal Advice



Other Legal





Other



Publication of Periodicals or Newsletters



Security Ratings or Pricing Services



Market Timing Services



Selection of Other Advisors



Educational seminars/workshops







See All Service Areas

	                Find
	            





Filters

/financial-planning/find/firm/



Compensation Arrangements



No Preference



Fixed Fees (14,450)



Hourly Charges (12,502)



Performance-Based Fees (6,657)



None (3,396)



Fee Only (75)






Assets Under Mgmt.



No Preference



0 - 100K (22,026)



1M - 10M (4,729)



10M - 100M (9,354)



100M - 500M (5,820)



1B - 10B (2,642)






Avg Account Balance



No Preference



0 - 100K (24,601)



100K - 500K (11,251)



500K - 1M (3,090)



1M - 10M (3,577)



10M - 100M (2,704)






Financial Advisory Firm Search Results


48,033 results










Merrill Lynch, Pierce, Fenner & Smith Incorporated
Ny, NY



34,605 Advisors
 | 
AUM : $639.6B











Wells Fargo Advisors, LLC
St. Louis, MO



26,648 Advisors
 | 
AUM : $409.7B











J.P. Morgan Securities LLC
Manhattan, NY



25,629 Advisors
 | 
AUM : $81.6B











Morgan Stanley Smith Barney LLC
Harrison, NY



24,260 Advisors
 | 
AUM : $598.5B











LPL Financial LLC
Boston, MA



18,591 Advisors
 | 
AUM : $117.2B











Edward D. Jones & Co., L.P.
Des Peres, MO



18,681 Advisors
 | 
AUM : $204.2B











Ameriprise Financial Services, Inc.
Minneapolis, MN



14,082 Advisors
 | 
AUM : $198.0B











UBS Financial Services Inc.
Weehawken, NJ



12,618 Advisors
 | 
AUM : $391.7B











Northwestern Mutual Investment Services,LLC
Milwaukee, WI



9,126 Advisors











Charles Schwab & Co., Inc.
South Beach, CA



7,895 Advisors











Mml Investors Services, LLC
Pine Point, MA



7,845 Advisors
 | 
AUM : $25.6B











Goldman, Sachs & Co.
Ny, NY



7,642 Advisors
 | 
AUM : $198.8B











Strategic Advisers, Inc.
Boston, MA



6,967 Advisors
 | 
AUM : $254.0B











Citigroup Global Markets Inc.
New York, NY



6,930 Advisors
 | 
AUM : $20.2B











Raymond James & Associates, Inc.
St. Petersburg, FL



6,389 Advisors
 | 
AUM : $125.0B









1
2
3
4
5



















Company Info
            About Us

Newsroom

Careers

Contact

Blog





Explore
            401K Plan Ratings

Advisor Pages

Fund Pages

Financial Insights

FAQ





For Advisors
            Advisor Pages

Spyglass





For Enterprise
            Beacon





Social
            Facebook

Twitter

LinkedIn





Legal
            Privacy Policy

Terms of Use






Copyright © 2008-2017, BrightScope Inc. All Rights Reserved. Your use of this service is subject to ourTerms of UseandPrivacy Policy





Information is provided 'as is' and solely for informational purposes, not for investment purposes or advice.BrightScope is not a fiduciary under ERISA. BrightScope is not endorsed by or affiliated with FINRA.
        










BrightScope /
CIO /
FWW /
Global Custodian /
Investor Economics /
LiquidMetrix /
Market Metrics /
Matrix Solutions /
PLANADVISER /
Plan For Life /
PLANSPONSOR /
Simfund /
Strategic Insight /
The Trade

©2016 Strategic Insight Inc. All Rights Reserved. No Reproduction without Prior Authorizations








































Sofinnova Ventures - Financial Services Firm, Menlo Park, California - BrightScope Advisor Pages































[[getSearchTypeDisplayName(searchType)]]


Advisor

Funds

Firms

401k Plans










































































Back to top



Home>FirmPages>Sofinnova Ventures





Sofinnova Ventures



OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees









Share


Sofinnova Ventures









OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees








Overview







Description
        
 Sofinnova Ventures is a RIA based in Menlo Park, CA with $2B in AUM.











Information


Type
RIA


HEAD QUARTERS
   Menlo Park, CA 




# OF EMPLOYEES
24


Total Assets
$1,693,657,901



Website







Location
        



3000 Sand Hill Rd


Menlo Park,
CA
94025


650-681-8420









Articles







Insights




There are no insights from this firm to display at this time.






Procter & Gamble Plans Competitive, But Exposure to Company Stock a Risk to Participants
BrightScope Editorial






Firm Links




There are no links for this firm to display at this time.









Holdings







ETF Holdings




There is no ETF holding data from this firm to display at this time.










Assets







Assets
Last updated on March 24, 2017





$1.7B
Total Assets Under Management


N/A
Total Assets Under Advisement






8

          
Accounts
          


$211.7M

          
Estimated Average Account Balance
          













Services







Firm Services
        




There is no Services data available to display at this time.








Firm Client types







Advisors









Current Advisors


# of advisors
0






There are no advisors from this firm to display at this time.





















Affiliated Investment Advisors and Broker Dealers



Name

Type

Total Assets





Sofinnova Bioequities Gp L.L.C.
              
--
              
--
              


Sofinnova Management Ix, L.L.C.
              
--
              
--
              


Sofinnova Management V 2005, L.L.C.
              
--
              
--
              


Sofinnova Management V, L.L.C.
              
--
              
--
              


Sofinnova Management Vi, L.L.C.
              
--
              
--
              


Sofinnova Management Vii, L.L.C.
              
--
              
--
              


Sofinnova Management Viii, L.L.C.
              
--
              
--
              


Sofinnova Management X, L.L.C
              
--
              
--
              


Sofinnova Ventures Verwaltungs Gmbh
              
--
              
--
              



















Leadership







Ownership




There is no ownership data available to display at this time.






Executives and Control Persons




Name

Title

Tenure Date

% Ownership





Alain Louis Azan

Shareholder And Director
      
June, 1997
      
10% to 25%
      


Michael Frank Powell

Shareholder, Director And Vice President
      
August, 1997
      
10% to 25%
      


Nathalie Marie Auber

Shareholder, Director And Chief Financial Officer
      
January, 1998
      
10% to 25%
      


James Irvin Healy

Shareholder, Director And President
      
June, 2000
      
10% to 25%
      


Anand No Middle Name Mehra

Shareholder, Director And Vice President
      
May, 2007
      
10% to 25%
      


Hooman No Middle Name Shahlavi

Shareholder, Secretary And General Counsel
      
February, 2007
      
5% to 10%
      


James Dennis Brody

Chief Compliance Officer
      
October, 2016
      
less than 5%
      










Source: SEC








Fees






Types of Compensation Arrangements


Percentage Of Assets

Performance-Based Fees

Other


















Company Info
            About Us

Newsroom

Careers

Contact

Blog





Explore
            401K Plan Ratings

Advisor Pages

Fund Pages

Financial Insights

FAQ





For Advisors
            Advisor Pages

Spyglass





For Enterprise
            Beacon





Social
            Facebook

Twitter

LinkedIn





Legal
            Privacy Policy

Terms of Use






Copyright © 2008-2017, BrightScope Inc. All Rights Reserved. Your use of this service is subject to ourTerms of UseandPrivacy Policy





Information is provided 'as is' and solely for informational purposes, not for investment purposes or advice.BrightScope is not a fiduciary under ERISA. BrightScope is not endorsed by or affiliated with FINRA.
        










BrightScope /
CIO /
FWW /
Global Custodian /
Investor Economics /
LiquidMetrix /
Market Metrics /
Matrix Solutions /
PLANADVISER /
Plan For Life /
PLANSPONSOR /
Simfund /
Strategic Insight /
The Trade

©2016 Strategic Insight Inc. All Rights Reserved. No Reproduction without Prior Authorizations




































SOFINNOVA MANAGEMENT VI, L.L.C. Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      SOFINNOVA MANAGEMENT VI, L.L.C.
                    

•   MENLO PARK, CA
                      
How do I update this listing?




                                             Sofinnova Management VI is based out of Menlo Park.   
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from SOFINNOVA MANAGEMENT VI, L.L.C., enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




sofinnova management vi, l.l.c.


3000 SAND HILL ROAD, 4-250

MENLO PARK
CA
                                                        
                                                    94025


                                                      Business Phone:
                                                      650-681-8420







Recent SEC Filings




4 filed on 10/24/2016
4 filed on 08/07/2014
3 filed on 07/31/2014
4 filed on 03/20/2014
4 filed on 07/17/2013
3 filed on 07/17/2013
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free


































Sofinnova Ventures - Financial Services Firm, Menlo Park, California - BrightScope Advisor Pages































[[getSearchTypeDisplayName(searchType)]]


Advisor

Funds

Firms

401k Plans










































































Back to top



Home>FirmPages>Sofinnova Ventures





Sofinnova Ventures



OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees









Share


Sofinnova Ventures









OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees








Overview







Description
        
 Sofinnova Ventures is a RIA based in Menlo Park, CA with $2B in AUM.











Information


Type
RIA


HEAD QUARTERS
   Menlo Park, CA 




# OF EMPLOYEES
24


Total Assets
$1,693,657,901



Website







Location
        



3000 Sand Hill Rd


Menlo Park,
CA
94025


650-681-8420









Articles







Insights




There are no insights from this firm to display at this time.






Procter & Gamble Plans Competitive, But Exposure to Company Stock a Risk to Participants
BrightScope Editorial






Firm Links




There are no links for this firm to display at this time.









Holdings







ETF Holdings




There is no ETF holding data from this firm to display at this time.










Assets







Assets
Last updated on March 24, 2017





$1.7B
Total Assets Under Management


N/A
Total Assets Under Advisement






8

          
Accounts
          


$211.7M

          
Estimated Average Account Balance
          













Services







Firm Services
        




There is no Services data available to display at this time.








Firm Client types







Advisors









Current Advisors


# of advisors
0






There are no advisors from this firm to display at this time.





















Affiliated Investment Advisors and Broker Dealers



Name

Type

Total Assets





Sofinnova Bioequities Gp L.L.C.
              
--
              
--
              


Sofinnova Management Ix, L.L.C.
              
--
              
--
              


Sofinnova Management V 2005, L.L.C.
              
--
              
--
              


Sofinnova Management V, L.L.C.
              
--
              
--
              


Sofinnova Management Vi, L.L.C.
              
--
              
--
              


Sofinnova Management Vii, L.L.C.
              
--
              
--
              


Sofinnova Management Viii, L.L.C.
              
--
              
--
              


Sofinnova Management X, L.L.C
              
--
              
--
              


Sofinnova Ventures Verwaltungs Gmbh
              
--
              
--
              



















Leadership







Ownership




There is no ownership data available to display at this time.






Executives and Control Persons




Name

Title

Tenure Date

% Ownership





Alain Louis Azan

Shareholder And Director
      
June, 1997
      
10% to 25%
      


Michael Frank Powell

Shareholder, Director And Vice President
      
August, 1997
      
10% to 25%
      


Nathalie Marie Auber

Shareholder, Director And Chief Financial Officer
      
January, 1998
      
10% to 25%
      


James Irvin Healy

Shareholder, Director And President
      
June, 2000
      
10% to 25%
      


Anand No Middle Name Mehra

Shareholder, Director And Vice President
      
May, 2007
      
10% to 25%
      


Hooman No Middle Name Shahlavi

Shareholder, Secretary And General Counsel
      
February, 2007
      
5% to 10%
      


James Dennis Brody

Chief Compliance Officer
      
October, 2016
      
less than 5%
      










Source: SEC








Fees






Types of Compensation Arrangements


Percentage Of Assets

Performance-Based Fees

Other


















Company Info
            About Us

Newsroom

Careers

Contact

Blog





Explore
            401K Plan Ratings

Advisor Pages

Fund Pages

Financial Insights

FAQ





For Advisors
            Advisor Pages

Spyglass





For Enterprise
            Beacon





Social
            Facebook

Twitter

LinkedIn





Legal
            Privacy Policy

Terms of Use






Copyright © 2008-2017, BrightScope Inc. All Rights Reserved. Your use of this service is subject to ourTerms of UseandPrivacy Policy





Information is provided 'as is' and solely for informational purposes, not for investment purposes or advice.BrightScope is not a fiduciary under ERISA. BrightScope is not endorsed by or affiliated with FINRA.
        










BrightScope /
CIO /
FWW /
Global Custodian /
Investor Economics /
LiquidMetrix /
Market Metrics /
Matrix Solutions /
PLANADVISER /
Plan For Life /
PLANSPONSOR /
Simfund /
Strategic Insight /
The Trade

©2016 Strategic Insight Inc. All Rights Reserved. No Reproduction without Prior Authorizations

































